Equities research analysts forecast that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will post earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.73). Zynerba Pharmaceuticals posted earnings per share of ($0.60) in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.7%. The business is scheduled to issue its next earnings results on Monday, March 11th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($2.94) to ($2.79). For the next financial year, analysts anticipate that the firm will report earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.23.
A number of research analysts have recently weighed in on ZYNE shares. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Saturday, November 17th. HC Wainwright set a $23.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 13th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Tuesday, October 2nd. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $17.75.
Shares of ZYNE opened at $4.82 on Monday. Zynerba Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $15.14. The company has a market cap of $84.96 million, a PE ratio of -1.94 and a beta of 4.49.
Hedge funds have recently added to or reduced their stakes in the business. Thompson Siegel & Walmsley LLC purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $157,000. Raymond James & Associates purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter worth approximately $164,000. GSA Capital Partners LLP purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $177,000. Zeke Capital Advisors LLC purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $193,000. Finally, Engineers Gate Manager LP purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter worth approximately $231,000. 15.24% of the stock is owned by hedge funds and other institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
See Also: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.